Drug Development

The application of molecular techniques to gastroenterology continues to yield important advances in the development of drugs to treat gastrointestinal disorders. Drug Development: Molecular Targets for Gastrointestinal Disease brings together a panel of distinguished experts to critically review the many promising new areas of gastrointestinal pharmacology at the molecular level. Key chapters discuss such major themes as the cyclooxygenase-2 inhibitors, the complexities of nitric oxide pathways in the gut, and the influence of cytokines on inflammatory bowel disease, as well as new opportunities for pharmacotherapy, including peptide growth factors, tachykinins-particularly substance P and neurokinins-cholecystokinin receptors, and serotonin. Also examined as possible sites for treating motility disorders and visceral pain are the opioid receptors residing in the gut, and the H3-receptor agonists for treating gut inflammation and pain. Drug Development: Molecular Targets for Gastrointestinal Disease provides a comprehensive review of today's molecular pharmacological approaches to the discovery and development of novel drugs for gastrointestinal and liver diseases. Its extensive references, richly experienced contributors, and cutting-edge syntheses of past, present, and emergent research establish the book as an essential resource for all pharmacologists, medicinal chemists, and clinicians seeking more powerful drugs for the prevention and treatment of gastrointestinal disorders. Timothy Gaginella and Antonio Guglietta bring together hands-on experts to critically review the many promising new areas of gastrointestinal pharmacology at the molecular level. Key chapters discuss such major themes as cyclooxygenase-2 inhibitors, the complexities of nitric oxide pathways in the gut, and the influence of cytokines on inflammatory bowel disease, as well as new opportunities for pharmacotherapy, including peptide growth factors, achykinins - particularly substance P and neurokinins - cholecystokinin receptors, and serotonin. Also examined as possible sites for treating motility disorders and visceral pain are the opioid receptors residing in the gut, and the H3-receptor agonists for treating gut inflammation and pain. Drug Development: Molecular Targets for Gastrointestinal Disease provides a comprehensive review of today's molecular pharmacological approaches to the discovery and development of novel drugs for gastrointestinal and liver diseases.